---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056248"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:17:29.905641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025

## Summary
- Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
- Cash, equivalents and marketable securities $239M after $161.8M public offering; runway extended into 2026.
- Positive Phase 2 dose exploration: nomlabofusp generally well-tolerated, dose-dependent frataxin increases in skin and buccal cells.
- First patient dosed in open-label extension (OLE) study of 25 mg daily; interim data on track for Q4 2024.
- BLA submission targeted second half 2025; FDA discussions underway for accelerated approval using frataxin as surrogate endpoint.

## SEC filing metadata
- accession: 0000950170-24-056248
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/lrmr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056248
- JSON: https://secwatch.observer/filing/0000950170-24-056248.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056248.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $14.7 million, EPS $0.27 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $14.7 million
  - EPS: $0.27 per share
  - Result: reported results
  source text: The Company reported a net loss for the first quarter of 2024 of $14.7 million, or $0.27 per share, compared to a net loss of $6.5 million, or $0.15 per share, for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.